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Postmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone
loss (AIBL) and fractures.
In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred
and three postmenopausal women with early breast cancer (EBC) were enrolled (osteoporotic, n¼25;
osteopaenic, n¼146; normal bone mineral density (BMD), n¼126). Weekly alendronate (70 mg) treatment
efﬁcacy as triggered by the algorithm in preventing bone loss was evaluated. All patients received anastrozole
(1 mg daily), calcium and vitamin D.
Results: All osteoporotic patients received alendronate at baseline. Eleven out of the 146 (7.5%) osteopaenic
patients commenced alendronate within 18 months of participation and eleven commenced after. One
hundred and twenty four out of the 146 (84.9%) osteopaenic patients and all 126 with normal baseline BMD
did not trigger the algorithm.
At three years, lumbar spine mean BMD increased (15.6%, po0.01) in the osteoporotic group. BMD in the
osteopaenic group with early intervention signiﬁcantly increased at three years (6.3%, p¼0.02). No signiﬁcant
change was seen in the late intervention group. No change was observed in those with osteopaenia without
alendronate.
There was a signiﬁcant drop in lumbar spine (5.4%) and hip (4.5%) mean BMD, in the normal BMD
group, none of whom received alendronate.
Fracture data will be presented.
Conclusion: In postmenopausal women with endocrine-responsive EBC, BMD improved over time when a
bisphosphonate is administered with anastrozole in osteoporotic patients using an osteoporosis schedule.
Subjects with normal baseline BMD experienced the greatest BMD loss, although none became osteoporotic.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The cancer survival rates in Australia from 1998 to 2004 indicates
that the majority of women diagnosed with breast cancer will
survive over the long term with 88.0% alive at ﬁve years and 79.4%
at ten years [1]. Extended survival exposes the majority of patients to
the late effects of breast cancer therapies. Osteoporosis and the
increased risk of associated skeletal related events are recognised as
undesirable outcomes of various adjuvant therapies for early breast
cancer [2]. Surveillance strategies for breast cancer need to incorpo-
rate monitoring for recurrence of disease as well as strategies to
prevent and manage the bone related complications of adjuvant
therapies.
Aromatase inhibitors in early breast cancer have demonstrated
greater efﬁcacy compared to tamoxifen in postmenopausal women
with improved disease free survival, time to recurrence and time
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to distant recurrence [3]. The suppression of oestrogen levels with
AIs results in accelerated bone mineral loss and increased fracture
risk. AIBL almost doubles the rate of loss seen in healthy post-
menopausal women [4]. Results from the ATAC sub-study demon-
strated that progressive AIBL occurs throughout the duration of
AI treatment. This is greater in the lumbar spine in the ﬁrst two
years of therapy commencement and the decline appears to be
less marked in years two to ﬁve of treatment but does not slow
down in the hip [5].
In 2005, Osteoporosis Australia proposed an algorithm [6]
to manage AIBL (Fig. 1). The algorithm assesses changes in bone
mineral density (BMD) and N-telopeptide (NTx, a bone resorption
marker) to determine timing of bisphosphonate therapy com-
mencement. The Bisphosphonate and Anastrozole Trial – Bone
Maintenance Algorithm Assessment (BATMAN) was designed
to test the utility of this algorithm in postmenopausal women
with hormone-receptor positive early breast cancer receiving
adjuvant anastrozole, and the efﬁcacy of intervention with alen-
dronate, given in an osteoporosis schedule. Most studies in this
area have excluded patients with osteoporosis due to the concern
of worsening BMD. This study speciﬁcally addresses the issues of
women with osteopaenia and osteoporosis in this setting.
2. Patients and method
Eligible participants were postmenopausal women with Stage
I–IIIa hormone receptor positive breast cancer assessed as suitable
for treatment with an aromatase inhibitor, speciﬁcally anastrozole.
Postmenopausal status was deﬁned as age 455 years with
cessation of menstruation; o55 years of age and no menses for
12 months;4 50 but o55 and amenorrhoeic (spontaneous,
hysterectomy) and with postmenopausal gonadotrophin or oes-
tradiol levels (luteinising hormone 414 IU/L, follicle stimulating
hormone levels 440 IU/L, oestradiol o110 pmol/L or according to
the reference range for the laboratory involved); or bilateral
oophorectomy. Following the observation of resumption of menses
and reversal of menopause in a number of patients all of whom
were under 50 years of age, we amended the entry criterion to
exclude women under 50 years. Hormone replacement therapy
must have been discontinued at least 2 weeks prior to registration.
Other eligibility requirements were WHO performance status r2,
with adequate renal and liver function.
Patients receiving prior treatments with bisphosphonates and
continuous systemic corticosteroids within the past 12 months
were excluded. Any prior use of parathyroid hormone (PTH) for
more than 1 week; systemic sodium ﬂuoride for 43 months
during the past 2 years; any drugs known to affect the skeleton
(eg. calcitonin, mithramycin, or gallium nitrate) were not allowed
prior to and during the study. Patients with history of diseases
with inﬂuence on bone metabolism (e.g. Paget′s disease, Osteo-
genesis Imperfecta, and primary or secondary hyperthyroidism),
lactose intolerance, delayed oesophageal emptying; previous or
concomitant malignancy within the past 5 years, were also
excluded. Patients with a fracture due to minimal trauma that
was detected on baseline radiology were excluded from the study.
Written informed consent was obtained from each patient
before inclusion. The study was approved by the Barwon Health
Human Research Ethics Committee (HREC), Eastern Health HREC,
St Vincent′s HREC, North Coast Area Health Service HREC, and
Sydney South West Area Health Service HREC. Eight Australian
oncology centres participated. These centres included Barwon
Health, St John of God Healthcare Geelong, South West
Healthcare (Warrnambool), Box Hill Hospital, Maroondah Hospital,
St. Vincent′s Hospital Melbourne, Tweed Hospital and Royal Prince
Alfred Hospital.
The study was conducted in accordance with the National
Health and Medical Research Council′s National Statement on
Ethical Conduct in Research Involving Humans (June 1999) and
the CPMP/ICH Notes for Guidance on Good Clinical Practice
(CPMP/ICH/135/95).
Osteoporosis was deﬁned as BMD 2.5 standard deviations or
more below the reference range mean for young adults. Osteo-
paenia being those with a BMD between 1 and 2.5 standard
deviations below the young adult mean [7]. Lumbar spine
(L2-L4) and femoral neck BMD was quantiﬁed with Lunar DPX-L
(Lunar, Madison, WI, USA), GE-Lunar Prodigy (Prodigy; GE Lunar,
Madison, WI, USA) or Norland Excell™ machines. Dual-energy
X-ray absorptiometry (DXA) at baseline, 1, 2 and 3 years assessed
using Norland machines were converted to Lunar equivalents
using the Genant conversion equations [8]. N-telopeptide (NTx)
is a marker of bone resorption. Urine samples for urinary
N-telopeptide (uNTx) were collected at baseline, and at 6 months
after registration. Participants requiring alendronate were retested
6 months after commencing alendronate.
All patients were commenced on oral anastrozole 1 mg daily,
calcium (Z 500 mg per day) and Vitamin D (Z 400 IU daily)
supplements. No dose modiﬁcations were permitted for the
duration of the study for those receiving either anastrozole or
alendronate.
In accordance with the OAA, patients with a BMD T-Score
below 2.5 S.D. at either the lumbar vertebra or femoral neck at
Fig. 1. Osteoporosis Australia bone maintenance algorithm, using T-score bone mineral density changes and urine Ntx elevation to guide bisphosphonate management.
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any time-point, were commenced on alendronate 70 mg oral
weekly. Patients with a T-score between 2.0 S.D. and 2.5 S.D.
commenced alendronate if the index of bone mineral turnover was
elevated 420% at the 6-month time-point. If the BMD T-Score fell
below 2.0 S.D. at either the lumbar vertebra or femoral neck at
any time during the ﬁve-year treatment period, bone mineral
turnover studies were instituted. If the bone mineral turnover
studies indicated that the biochemical marker (uNTx) was ele-
vated more than 20% over baseline, then bisphosphonate therapy
was instituted.
Patients were reviewed at 3 monthly intervals in years one and
two, and 6 monthly until year 5 with clinical examination and a
yearly mammogram.
In this 3-year analysis, we assessed the change in both lumbar
vertebra (L2 to L4) and femoral neck BMD at 12 monthly intervals.
We also assessed the beneﬁt of alendronate with respect to uNTx
and BMD in protecting bone health. The clinical fracture incidence
cumulative over 3 years was evaluated.
Different inﬂuences on lipid proﬁles have been observed in
trials comparing aromatase inhibitors to tamoxifen [9]. For safety
reasons, a fasting lipid assessment (LDL, HDL, total cholesterol and
triglycerides) was measured at baseline and repeated at the
6-month trial visit for all participants. Vitamin D level was
measured at baseline.
3. Statistical analysis
BMD was analysed using a repeated measures model that impli-
citly allowed for missing data and assessed dependent samples over
time with the multiple comparison Tukeys test applied. The level of
signiﬁcance was set at p¼0.05.
4. Results
4.1. Study population
Between September 2005 and June 2010, 303 patients from
8 Australian centres were enrolled, 297 were eligible for the study
(Fig. 2). At baseline, 25 (8.4%) were classiﬁed as having osteoporo-
sis, 146 (49.2%) were osteopaenic and 126 (42.1%) patients had
normal BMD. All of the 25 osteoporotic patients commenced
alendronate at baseline. Twenty-two osteopaenic patients were
determined by the algorithm to be eligible for alendronate during
the trial period but 1 patient refused. One osteopaenic patient
received alendronate off trial after a non-traumatic fracture.
One hundred and twenty four osteopaenic patients did not require
alendronate. Only 2 of the patients with normal BMD were treated
with alendronate, after a clinical fracture event, without triggering
the algorithm and were excluded from this time point.
Table 1 shows the baseline characteristics of the study popula-
tion. Patients in the normal baseline BMD subgroup tended to be
younger. The mean age was higher for the patients in the early
intervention (o18 months from commencing alendronate) osteo-
paenic group in comparison to the late intervention (Z18 months)
group. BMD was higher in the osteopaenic group that received late
and no intervention. In the osteopaenic subgroup, there were
2 patients that had previous axillary clearance for a prior breast
cancer and hence lymph node stage was not determined for the
current breast cancer. All patients′ tumours were oestrogen
receptor (ER) and/or progesterone receptor (PR) positive.
4.1.1. BMD results
4.1.1.1. Osteoporotic patients. BMD of the spine at baseline was
0.91470.028 g/cm2 (mean7SE) and signiﬁcantly increased to
Fig. 2. Consort diagram enrolment and outcomes are shown. a6 ineligible (5 had compression fracture at baseline, 1 with hyperthyroidism at baseline) b1 patient refused.
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0.98070.026 g/cm2 at 1 year (po0.01), 1.01270.032 g/cm2 at
2 years (po0.01) and 1.05770.049 g/cm2 at 3 years (po0.01),
(Fig. 3a). This equates to an increase of 7.2%, 10.7% and 15.6%
respectively, from baseline. Similarly, BMD of the hip was
0.71870.014 g/cm2 (baseline), 0.74370.018 g/cm2 (1 year),
0.75270.024 g/cm2 (2 years) and 0.77470.033 g/cm2 (3 years),
(all po0.01) with a signiﬁcant increase of 3.5%, 4.7% and 5.6%,
respectively, (Fig. 4a).
4.1.1.2. Osteopaenic patients with alendronate (early intervention). BMD
of the spine at baseline was 1.00970.021 g/cm2 (mean7SE) and was
not signiﬁcantly different at 1.00270.028 g/cm2 (p¼0.73) at 1 year,
however, there was a trend towards an increase at 2 years 1.0497
0.032 g/cm2 (p¼0.19) and signiﬁcance at 3 years 1.07370.041 g/cm2
(6.3%, p¼0.02), (Fig. 3b). BMD of the hip was 0.77170.029 g/cm2
(baseline), 0.77270.033 g/cm2, 0.78670.029 g/cm2 and 0.7887
0.053 g/cm2 with no signiﬁcant change, (Fig. 4b).
4.1.1.3. Osteopaenic patients with alendronate (late intervention). BMD
of the spine at baseline was 1.09470.042 g/cm2 (mean7SE) and
was 1.07970.045 g/cm2 at 1 year, 1.07770.050 g/cm2 at 2 years and
1.08170.061 g/cm2 at 3 years, (Fig. 3c). There was no signiﬁcant
change from baseline. Similarly, BMD of the hip was 0.80970.020
g/cm2 (baseline), 0.79270.024 g/cm2 9(1 year), 0.77470.022 g/cm2
at 2 years and 0.77170.022 g/cm2 at 3 years with no signiﬁcant
change, (Fig. 4c).
4.1.1.4. Osteopaenic patients without alendronate. BMD of the spine at
baseline was 1.11270.012 g/cm2 (mean7SE) at baseline, 1.0977
0.014 g/cm2 at 1 years, 1.08870.015 g/cm2 at 2 years and 1.100
70.021 g/cm2 at 3 years, (Fig. 3d). This equates to a non-signiﬁcant
decrease of 1.3%, 2.2% and 1.0% respectively, from baseline. Similarly,
BMD of the hip was 0.84770.006 g/cm2 (baseline), 0.83470.008 g/
cm2 (1 year), 0.83070.009 g/cm2 (2 years) and 0.83070.008 g/cm2
(3 years) with a decrease of 1.5% (p¼0.18), 2.0% (p¼0.04) and 1.7%
(p¼0.25), respectively, (Fig. 4d).
4.1.1.5. Patients with normal BMD. BMD of the spine at baseline
was 1.26370.011 g/cm2 (mean7SE) and signiﬁcantly decreased
to 1.21970.013 g/cm2 at 1 year (p¼0.03), 1.22470.017 g/cm2 at
2 years (p¼0.07) and 1.19570.016 g/cm2 at 3 years (po0.01),
(Fig. 3e). This equates to a decrease of 3.5%, 3.1% and 5.4%
respectively, from baseline. Similarly, BMD of the hip was
1.00170.008 g/cm2 (baseline), 0.97270.009 g/cm2 (1 year),
0.95670.011 g/cm2 (2 years) and 0.95670.013 g/cm2 (3 years)
with a decrease of 2.9% (po0.01), 4.6% (po0.01) and 4.5%
(po0.01), respectively, (Fig. 4e). No patients in this subgroup
became osteoporotic.
4.1.1.6. Three year non traumatic fracture rates. There was 1 (3.85%)
non-traumatic fracture in the osteoporotic subgroup over the 3 years
period. There were no non-traumatic fractures in the osteopaenic
subgroup that received alendronate. The osteopaenic subgroup that
did not have alendronate had 10 (8.06%) non-traumatic fractures over
3 years. 2 (1.59%) non-traumatic fractures were documented in the
normal BMD group.
4.1.1.7. Markers of bone turnover. The osteoporotic subgroup
commencing alendronate at baseline demonstrated a drop in uNTx
of 38% after 6 months of treatment. No patients in the osteopaenic
and normal BMD subgroups received alendronate in the ﬁrst
6 months. Their uNTx had increased by 24% and 51%, respectively.
4.1.1.8. Vitamin D levels. Vitamin D levels were checked at
baseline in 291 of the 297 eligible patients. 34% (99/291) of
patients had a baseline vitamin D level o50 nmol/L consistent
with vitamin D deﬁciency (Fig. 5). 3.4% (10/291) patients had
moderate to severe vitamin D deﬁciency (o25 nmol/L).
The majority (75%) of patients were recruited from southern
Table 1
Patient baseline characteristics.
Characteristics
number (%)
Osteoporotic 25 (8.4%) Osteopaenic with
alendronate (early
Intervention) 11 (3.7%)
Osteopaenic with
alendronate (late
intervention) 11 (3.7%)
Osteopaenic without
alendronate 124
(41.8%)
Normal BMD 126
(42.4%)
Age, year
Mean7S.D. 64.1710.3 70.578.3 61.276.0 62.377.6 57.179.2
BMI
Mean 28.676.5 28.675.7 31.177.3 28.275.2 30.276.3
ECOG
0 20 (80.0%) 9 (81.8%) 10 (90.9%) 108 (87.1%) 111 (88.1%)
1 5 (20.0%) 2 (18.2%) 1 (9.1%) 16 (12.9%) 15 (11.9%)
2 0 0 0 0 0
Baseline BMD (mean)
L. spine7SD 0.91470.028 1.00970.069 1.09470.140 1.112 70.0138 1.26370.125
Hip7SD 0.71870.014 0.77170.094 0.80970.066 0.84770.065 1.00170.095
Stage
I 8 (32.0%) 3 (27.3%) 5 (45.5%) 47 (37.9%) 41 (32.5%)
II 14 (56.0%) 6 (54.5%) 3 (27.3%) 50 (40.3%) 68 (54.0%)
III 3 (12.0%) 2 (18.2%) 3 (27.3%) 25 (20.2%) 17 (13.5%)
Previous Axillary
clearance
NA NA NA 2 (1.6%) NA
ER
Positive 23 (92.0%) 11 (100.0%) 11 (100.0%) 123 (99.2%) 120 (95.2%)
Negative 2 (8.0%) 0 0 1 (0.8%) 6 (4.8%)
PR
Positive 19 (76.0%) 9 (81.8%) 7 (63.6%) 105 (84.7%) 102 (81.0%)
Negative 6 (24.0%) 2 (18.2%) 4 (36.4%) 19 (15.3%) 24 (19.0%)
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Victoria with an approximate latitude of 381S. The remaining
72/291 patients were from more northerly states with latitudes
of 33.91S (Sydney,) and 28.21S (Tweed Heads). The mean
vitamin D levels were 62.13, 48.5 and 61.47 (nmol/L)
respectively. Data was adjusted for age and the season during
which the measurements were taken.
4.1.1.9. Lipid. There was no signiﬁcant change in the lipid proﬁle after
6 months of anastrozole.
4.1.1.10. Reason for discontinuation. 78 participants withdrew from the
study by 36 months.
Most (39.7%) patients withdrew from the study due to
anastrozole-related adverse events (AEs), which included
myalgias, arthralgias, hot ﬂushes, tenosynovitis and fractures
(Table 2). Only 5 patients withdrew due to bisphosphonate-
related AEs, which were largely due to gastrointestinal side
effects. There were no cases of osteonecrosis of the jaw. Four
patients had less than 12 months, and a further ﬁfty between
12 and 24 months follow up. Nine (3%) patients experienced
Fig. 3. Mean change (g/cm2) in lumbar spine BMD in (a) osteoporotic subgroup (n¼25), (b) osteopaenic subgroup with early alendronate, n¼11, (c) osteopaenic group with
late alendronate (n¼11), (d) osteopaenic group without alendronate (n¼124) and (e) normal BMD subgroup (n¼126).
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return of ovarian function while on anastrozole, necessitating
discontinuation of their trial participation. They were all aged
r50 years and most of these had experienced chemotherapy-
induced menopause.
5. Discussion
Based on the results of this three-year analysis, alendronate
effectively increases BMD in osteoporotic, postmenopausal women
with early breast cancer who are receiving adjuvant therapy with
anastrozole. This subgroup of women would have the greatest risk of
bone loss and fracture. The beneﬁt seenwith bisphosphonate therapy
was greater at the spine than at the hip but did signiﬁcantly improve
both spine and hip BMD (15.6%, po0.01 and 5.6%, po0.01 at 3 years
respectively). Prior studies, such as Z-FAST [10], have mostly reported
the impact of bisphosphonates on BMD in women with osteopaenia.
Our ﬁndings are consistent with the results from the ARIBON trial
that included 13 osteoporotic women who received anastrozole and
ibandronate contributing to an increased BMD of 3.52% and 2.49% for
Fig. 4. Mean change (g/cm2) in hip BMD in (a) osteoporotic subgroup (n¼25), (b) osteopaenic subgroup with early alendronate (n¼11), (c) osteopaenic group with late
alendronate (n¼11), (d) osteopaenic group without alendronate (n¼124) and (e) normal BMD subgroup (n¼126).
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the lumbar spine and hip at 2 years [11]. Subsequent results of this
study continue to show an increase in lumbar BMD (9.65%) and at the
hip (2.72%) for the 9/13 patients in the osteoporotic group when
assessed at their 5 year follow-up, demonstrating the ability to use AI
therapy currently with a bisphosphonate in these women [12]. Our
study also conﬁrms the safety of commencing aromatase inhibitors in
this frequently excluded sub-group.
BMD of the spine, but not at the hip, demonstrated a signiﬁcant
increase of 6.3%, p¼0.02 at 3 years in the osteopaenic group
receiving early intervention with alendronate. However, we did not
demonstrate an improvement in BMD for the osteopaenic group
receiving late intervention with alendronate. Patient numbers were
small and larger beneﬁt might be expected with longer follow 'up' of
these patients. These late intervention patients triggered the algo-
rithm and started on alendronate at different time points (o18
months; 18–24 months; 24–36 months; 436 months). This results
in a confounding proportion of patients within this group with
ongoing BMD loss prior to starting bisphosphonate therapy.
The mean time to the introduction of alendronate was 21.5
months in the osteopaenic group. With this delay in institution of
alendronate there has been limited observation time post inter-
vention. An additional reason for the small or lack of demonstrable
beneﬁt from early and late alendronate in the osteopaenic group
respectively, is our use of the baseline BMD as the comparator. This
introduces a bias against the therapy BMD end point, as the BMD
further reduced prior to the intervention. Perhaps with a longer
follow-up period of 5 years this may allow better demonstration of
the protective effect of bisphosphonate therapy.
In the normal BMD subgroup, there was progressive bone loss
over 3 years at the spine and hip (5.4% and 4.5%, respectively). This
ﬁnding is consistent with the ATAC data [5]. Two patients required
alendronate triggered by clinical events but there were no algo-
rithm triggered events. There were no non-traumatic fractures
reported in the osteopaenic group receiving alendronate com-
pared with 8% in the group without alendronate. The osteoporotic
patients would be presumed to have a higher fracture rate than
the osteopaenic group associated with lower baseline BMD. The
non-traumatic fracture rate in the osteoporotic group receiving
alendronate was lower in comparison to the osteopaenic group
without alendronate. Overall this suggests a protective effect of
alendronate. However, these results should be interpreted with
caution because the study was not adequately powered to detect a
difference in fracture rates.
Eleven osteopaenic patients progressed to osteoporosis with
T scores r2.5 but this was not observed for patients with
a normal baseline BMD. The intervention rate, with the Osteo-
porosis Australia Algorithm, for introducing alendronate to the
patients with osteopaenia (15.1%) was lower than we had
expected. Given that 27% of Australian women aged 60 and over
are considered osteoporotic and 51% [7] are osteopaenic, it was
expected that approximately 75% of women accrued would
require bisphosphonate therapy. The high rate, 8%, of low trauma
fractures we observed in osteopaenic patients without alendro-
nate suggests that the algorithm threshold may be set too high in
this group. In the ATAC study, fracture rates were constant during
the period of treatment [9]. More fractures were reported in the
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Table 2
Reason for discontinuation.
Osteoporotic with
alendronate n¼25
Osteopaenic with
alendronate n¼22
Osteopaenic without
alendronate n¼124
Normal BMD n¼126
Number of discontinuations n¼5 (20%) n¼5 (22.7%) n¼36 (29%) n¼32 (25.4%)
AI related AE 19 12
Bisphosphonate related AE 2 1 2
Relapse/recurrence 3 3
Pt decision 1 2 4 5
Death 1
Other 2 1 8 12
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anastrozole than tamoxifen group but then were similar after the
completion of treatment. There was no protocol for bone health
maintenance in this study and bisphosphonate use was low at 10%
and 7% in these groups respectively [3].
Our patients in the osteopaenic group receiving early interven-
tion had a mean BMD of 1.009 g/cm2, equivalent to a T score of
1.7. The ATAC sub-study found that 5 women with osteopaenia
at baseline (4 in the anastrozole group and 1 receiving tamoxifen)
developed osteoporosis. They evaluated the T-scores from baseline
to 5 years with linear regression, and found that a T-score of 1.5
may deﬁne risk for the development of osteoporosis as no patients
with a higher T-score dropped to o2.5 on treatment [5].
The UK expert group have suggested an alternative algorithm.
In postmenopausal women with a T-score that falls below 2.0 or
if the rate of bone loss is more than 4% per year with pre-existing
osteopenia, a bisphosphonate is recommended [13]. This prag-
matic recommendation avoids the need to measure uNTx which is
expensive and unwieldy. A simpliﬁed algorithm, omitting uNTx
but taking into account major risk factors for osteoporotic fracture
may have more clinical utility.
Vitamin D deﬁciency is common in our community and
contributes adversely to bone health, and to breast cancer out-
comes. It is associated with reduced BMD and osteoporosis.
Although most studies focused on the elderly population, appro-
priate vitamin D supplementation is an important modiﬁable risk
factor for reducing falls and fractures [14]. All the participants in
our trial received 400–500 IU of oral vitamin D daily regardless of
their baseline vitamin D levels. One third of our patients had
vitamin D deﬁciency. We did not see a gradient in mean vitamin D
levels between patients from more northerly states and Southern
Victoria. This high level of vitamin D deﬁciency in our patients is
comparable to that found in our community regardless of season
and latitude. The reported prevalence of vitamin D insufﬁciency
(r50 nmol/L) in women during winter/spring was 40.5%, and
37.4% in southeast Queensland (latitude 28.21S), and Geelong
(381S) [15]. According to the Working Group of the Australian
and New Zealand Bone and Mineral Society, Endocrine Society of
Australia and Osteoporosis Australia, higher doses of vitamin D up
to 3000–5000 IU daily for 6–12 weeks are required to replete body
stores, followed by 1000 IU daily as maintenance [16]. Treatment
of vitamin D deﬁciency was a decision of the investigator clinician.
Our analysis also showed that there were no meaningful lipid
changes with anastrozle, as a surrogate for cardiovascular health.
This is in keeping with the TEAM Japan [17], TEAM Greek [18] sub-
studies and the SABRE trial [19], which showed that AIs have no
detrimental effects on lipid parameters. This is reassuring when
using AIs in women with favourable prognosis breast cancer.
Three percent of the participants reported return of ovarian
function while receiving adjuvant anastrozole. This raises concern
that these patients were exposed to a period of inadequate
adjuvant therapy as the anticancer effects from AIs would be
abrogated due to return of ovarian production of oestradiol. AI′s
may in fact induce ovulation [20]. Smith et al. suggested guidelines
for patients with chemotherapy induced amenorrhoea recom-
mending that women o40 years old should not receive an
AI alone as adjuvant treatment [21]. These guidelines were not
published prior to the commencement of the trial. For women
older than 40 years, it was suggested that serial monitoring of
sexual hormone levels should be performed and requires
a sensitive assay. We have observed reversal of chemotherapy-
induced menopause in patients up to age 49 years. An alternative
is to use tamoxifen alone, with the option of a later switch or an
AI with concurrent ovarian function suppression. Women in this
age group should be informed of the possibility of return of
ovarian function and to report menstrual bleeding or the cessation
of hot ﬂushes to their treating oncologists [21]. The reversals of
ovarian function were all in women under 50, and we amended
the entry criterion to exclude this age group.
6. Conclusions
Aromatase inhibitor induced bone loss is less dramatic than
expected, can be managed and does not contraindicate AI use.
Osteoporosis dose intensity bisphosphonates are sufﬁcient for
these patients in regard to bone health [22]. The Osteoporosis
Australia algorithm proved cumbersome involving expensive bio-
chemical tests of bone turnover, and has a high threshold.
A simpler algorithm with a T score threshold of 2.0 as stated
in the UK recommendation may be clinically useful.
This study conﬁrms that it is safe to prescribe anastrozole in
osteoporotic post-menopausal women with early breast cancer,
when used together with a bisphosphonate. No patient with
normal baseline BMD became osteoporotic. A randomised con-
trolled study would need to be performed to validate these results
given some subgroups had small patient numbers.
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